^
    3years
    Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing. (PubMed, Eur J Cancer)
    The mechanisms of ALK TKI resistance were heterogeneous; ALK mutations were found in less than one-third of patients. Compound ALK mutations, which may confer lorlatinib resistance, may occur in crizotinib, ceritinib, and alectinib-resistant lung cancers.
    Clinical • Journal • Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    BRAF V600E • EGFR mutation • NRAS mutation • PIK3CA mutation • BRAF V600 • ALK rearrangement • KIT mutation • PIK3CA E545K • MET mutation • ALK G1202R • NRAS G12 • ALK G1269A • ALK I1171T • PIK3CA E545 • ALK I1171 • ALK L1196M • ALK E1210K • ALK D1203N • ALK G1128A • ALK rearrangement + PIK3CA mutation • EGFR P753S • NRAS G12V • KIT D820E
    |
    Xalkori (crizotinib) • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • Alunbrig (brigatinib)